Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43889   clinical trials with a EudraCT protocol, of which   7298   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2005-003351-12
    Sponsor's Protocol Code Number:A6141079
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2005-10-07
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2005-003351-12
    A.3Full title of the trial
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberA6141079
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberN/A
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInspra
    D.3.2Product code N/A
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEplerenone
    D.3.9.1CAS number 107724-20-9
    D.3.9.3Other descriptive nameMethyl hydrogen (7α,11α,17α)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylateγ-lactone
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product Information not present in EudraCT
    D. ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D. on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic systolic heart failure
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 8.0
    E.1.2Level LLT
    E.1.2Classification code 10008908
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this trial is to evaluate the efficacy and safety of eplerenone plus standard heart failure (HF) therapy versus placebo plus standard HF therapy on the cumulative incidence of cardiovascular (CV) mortality and HF hospitalisation (a composite primary endpoint).
    E.2.2Secondary objectives of the trial
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

    1. Written informed consent obtained prior to the initiation of any study procedures.

    2. Male or female subjects, ≥55 years of age at the time informed consent is obtained

    3. Chronic systolic heart failure (HF) of either ischemic or non-ischemic etiology,

    a. Duration: at least 4 weeks.

    b. Left ventricular ejection fraction (LVEF): ≤30% by echocardiography, contrast ventriculography, magnetic resonance imaging or nuclear imaging, based on local clinical practice. The most recent measurement within 6 months prior to randomization must be used.


    Left ventricular ejection fraction (LVEF) ≤35% in addition to QRS duration ≤130 msec. It is mandatory that subjects with LVEF 31-35% must also have QRS duration ≤130 msec to be eligible for this trial.

    c. Functional Capacity: Currently NYHA II (in the investigator’s opinion).

    d. Treatments (for ACE inhibitors, ARBs and β-blockers, optimal target or maximal tolerated dose unless contraindicated).

    • Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs).

    • β-blocker.

    • Diuretic, if clinically indicated to reduce fluid retention.

    4. Serum potassium (K+) level ≤5.0mmol/L within 24 hours prior to randomization.

    5. Estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73m2 within 24 hours
    prior to randomization.

    6. Randomization must occur no later than 6 months from the date of admission to
    hospital for a cardiovascular reason (see definition of cardiovascular hospitalization
    below). If the subject is clinically stable, he or she may be randomized during
    admission for a cardiovascular reason.


    In the absence of a recent admission to hospital for a cardiovascular reason,
    documentation of a plasma concentration of B-type natriuretic peptide (BNP) of at
    least 250 pg/ml or amino-terminal proB-type natriuretic peptide (NT-proBNP) of at
    least 500 pg/ml for males and 750 pg/ml for females, within 15 days of randomization.

    7. If the subject is a female, the following should apply.

    a. Have a negative serum pregnancy within 72 hours prior to the first dose of
    study drug, except if she previously had a total hysterectomy or is >65 years old.

    b. Agree to use an adequate form of contraception (Abstinence will not be
    considered an acceptable form of contraception) if she is of child-bearing potential.

    8. Subjects previously treated with an aldosterone antagonist for >7 consecutive days will be allowed if they fulfill the following criteria:

    a. No history of clinically significant hyperkalemia or renal impairment during
    earlier use of an aldosterone antagonist.

    b. The aldosterone antagonist must have been discontinued for at least 3 months
    prior to randomization.

    A washout period of 48 hours is deemed adequate for subjects treated with an aldosterone antagonist for fewer than 7 days. Subjects who have a bona fide need for an aldosterone antagonist must not be discontinued from treatment just to make them eligible for entry into this trial.

    9. Subjects in whom the primary cause of heart failure is inoperable valve disease.
    E.4Principal exclusion criteria
    1. Patients with severe chronic systolic heart failure, defined as patients who
    demonstrate symptoms usually at rest despite optimal medical therapy.

    2. Patients with a myocardial infarction complicated by left ventricular systolic
    dysfunction and clinical heart failure within 30 days prior to randomization.

    3. Patients with stroke within 30 days prior to randomization.

    4. Patients who have had cardiac surgery within 30 days prior to randomization.

    5. Patients who have had percutaneous coronary intervention (PCI) within 30 days
    prior to randomization.

    6. Patients previously exposed to treatment with an aldosterone antagonist for >7
    consecutive days, in whom the aldosterone antagonist has not been discontinued
    permanently for at least 3 months prior to randomization, or patients who have a
    history of clinically significant hyperkalemia or renal impairment during a previous
    exposure to an aldosterone antagonist.

    7. Patients who require treatment with eplerenone, spironolactone or potassium
    canrenoate and either have prior NYHA class IV heart failure associated with a
    LVEF <0.35 (as in the RALES trial) [2] or heart failure or diabetes and a LVEF <0.40 after acute MI (as in EPHESUS trial).

    8. Patients with uncontrolled hypertension, defined as having a systolic blood pressure >180 mmHg and/or a diastolic blood pressure >110 mmHg.

    9. Patients with symptomatic hypotension or having a systolic blood pressure <85 mmHg.

    10. Patients, who in the opinion of the investigator, require treatment with potassium-sparing diuretics.

    11. History of hypersensitivity to eplerenone or spironolactone.

    12. Evidence of cardiogenic shock.

    13. Patients in whom the primary cause of heart failure is surgically amenable valve
    disease, pericardial disease or an obstructive or restrictive cardiomyopathy.

    14. Intra-aortic balloon pump or other mechanical assist device.

    15. Patients awaiting cardiac transplantation.

    16. Serum potassium >5.0 mmol/L within 24 hours prior to randomization.

    17. Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2 within 24 hours
    prior to randomization.

    18. Concomitant use of potent cytochrome p450 3A4 (CYP3A4) inhibitors, such as but
    not limited to:
    a. Ketoconazole

    b. Itraconazole

    c. Nefazodone

    d. Troleandomycin

    e. Clarithromycin

    f. Ritonavir

    g. Nelfinavir

    19. Concomitant use of cytochrome p450 3A4 (CYP3A4) inducers, such as but not
    limited to:
    a. St. John’s Wort

    b. Rifampin

    c. Carbamazepine

    d. Phenytoin

    e. Phenobarbitol

    20. Hemoglobin <10g/dL

    21. Patients with preexisting significant hepatic disease (for example, known positive
    serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine
    aminotransferase (ALT) >3 times the upper limits of normal

    22. Patients status-post gastric bypass surgery, partial gastrectomy or other surgery of the gastrointestinal tract that may interfere with the absorption of eplerenone

    23. Patients with preexisting serious conditions (eg, cancer, Acquired Immunodeficiency Syndrome (AIDS). Patients with a previous history of cancer will be eligible if in the opinion of the investigator life expectancy is anticipated to be greater than 5 years.

    24. Patients unable to give written informed consent

    25. Patients with a progressively fatal disease (except congestive heart failure) and/or life expectancy less than 3 years

    26. Patients receiving immunosuppressive or antineoplastic therapy

    27. Patients with a history of alcohol and/or any other drug abuse that in the opinion of the investigator will make the patient unreliable

    28. Patients who previously participated in this trial

    29. Patients who are likely to require treatment during the trial period with drugs not
    permitted by this protocol

    30. Women who are either pregnant, lactating or of childbearing potential and not
    using an acceptable method of contraception

    31. Donation of blood or blood products for transfusion at any time during the trial or
    until 30 days after completion of treatment

    32. Participation in any other trial involving investigational or marketed products
    (including devices) concomitantly or within 30 days prior to entry in the trial

    33. Other severe acute or chronic medical or psychiatric condition or laboratory
    abnormality that may increase the risk associated with trial participation or
    investigational product administration or may interfere with the interpretation of
    trial results and, in the judgment of the investigator, would make the subject
    inappropriate for entry into this trial.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the first occurrence of cardiovascular (CV) mortality and heart failure (HF) hospitalisation.

    Cardiovascular (CV) mortality is defined as death due to:
    Heart Failure
    Myocardial infarction
    Cardiac arrhythmia
    Stroke/cerebral vascular accident (CVA) or transient ischaemic attack (TIA)
    Other CV cause (e.g., aneurysm or pulmonary embolism)

    Hospitalisation for HF:

    Hospitalization for HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) with a discharge diagnosis that includes a CV reason for hospitalization.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other Yes
    E. description
    Standard Therapy
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned18
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA172
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    As per protocol.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state200
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1718
    F.4.2.2In the whole clinical trial 3102
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    As per protocol
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2005-11-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2006-02-21
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2012-01-24
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands